JPWO2019209083A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019209083A5 JPWO2019209083A5 JP2020560378A JP2020560378A JPWO2019209083A5 JP WO2019209083 A5 JPWO2019209083 A5 JP WO2019209083A5 JP 2020560378 A JP2020560378 A JP 2020560378A JP 2020560378 A JP2020560378 A JP 2020560378A JP WO2019209083 A5 JPWO2019209083 A5 JP WO2019209083A5
- Authority
- JP
- Japan
- Prior art keywords
- methylene
- pyrazole
- thioxo
- thiazolidin
- thiazolidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 12
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 7
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 7
- 206010003805 Autism Diseases 0.000 claims 6
- 208000020706 Autistic disease Diseases 0.000 claims 6
- 208000014644 Brain disease Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 230000037361 pathway Effects 0.000 claims 5
- 201000002847 Cowden syndrome Diseases 0.000 claims 4
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- -1 Isopropylphenyl Chemical group 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Chemical group 0.000 claims 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 208000012609 Cowden disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 2
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- LYIXMODIYANFIG-XFFZJAGNSA-N (5Z)-3-(2-hydroxyethyl)-5-[(1-pyridin-2-ylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound OCCN1C(S\C(\C1=O)=C/C=1C=NN(C=1)C1=NC=CC=C1)=S LYIXMODIYANFIG-XFFZJAGNSA-N 0.000 claims 1
- JOHPVLNQJQIJRO-WZUFQYTHSA-N (5Z)-3-(furan-2-ylmethyl)-5-[(1-methylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O1C(=CC=C1)CN1C(S\C(\C1=O)=C/C=1C=NN(C=1)C)=S JOHPVLNQJQIJRO-WZUFQYTHSA-N 0.000 claims 1
- MEENHJVAEMSFKM-JYRVWZFOSA-N (5Z)-3-ethyl-5-[(1-phenylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C(C)N1C(S\C(\C1=O)=C/C=1C=NN(C=1)C1=CC=CC=C1)=S MEENHJVAEMSFKM-JYRVWZFOSA-N 0.000 claims 1
- LDLNVNAFDUZFQO-ZSOIEALJSA-N (5Z)-3-ethyl-5-[[1-(4-methylphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C(C)N1C(S\C(\C1=O)=C/C=1C=NN(C=1)C1=CC=C(C=C1)C)=S LDLNVNAFDUZFQO-ZSOIEALJSA-N 0.000 claims 1
- RUTWYDZVKHCMJD-SXGWCWSVSA-N (5Z)-3-ethyl-5-[[1-(4-propan-2-ylphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C(C)N1C(S\C(\C1=O)=C/C=1C=NN(C=1)C1=CC=C(C=C1)C(C)C)=S RUTWYDZVKHCMJD-SXGWCWSVSA-N 0.000 claims 1
- KORKYJFLNYCLCO-QPEQYQDCSA-N (5Z)-3-methyl-5-[[1-(4-methylphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound CN1C(S\C(\C1=O)=C/C=1C=NN(C=1)C1=CC=C(C=C1)C)=S KORKYJFLNYCLCO-QPEQYQDCSA-N 0.000 claims 1
- HWBCLOCODQAXNI-CHHVJCJISA-N (5Z)-5-[(1-naphthalen-2-ylpyrazol-4-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1=C(C=CC2=CC=CC=C12)N1N=CC(=C1)\C=C/1\C(NC(S\1)=O)=O HWBCLOCODQAXNI-CHHVJCJISA-N 0.000 claims 1
- BJJUBBHKVOGRLA-FLIBITNWSA-N (5Z)-5-[(1-phenylpyrazol-3-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1(=CC=CC=C1)N1N=C(C=C1)\C=C/1\C(NC(S\1)=O)=O BJJUBBHKVOGRLA-FLIBITNWSA-N 0.000 claims 1
- ZQZWHNYJDVSBNC-CLFYSBASSA-N (5Z)-5-[(1-pyridin-2-ylpyrazol-3-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound N1=C(C=CC=C1)N1N=C(C=C1)\C=C/1\C(NC(S\1)=O)=O ZQZWHNYJDVSBNC-CLFYSBASSA-N 0.000 claims 1
- YSPVLADFQCURFJ-CLFYSBASSA-N (5Z)-5-[(1-pyridin-2-ylpyrazol-3-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound N1=C(C=CC=C1)N1N=C(C=C1)\C=C/1\C(NC(S\1)=S)=O YSPVLADFQCURFJ-CLFYSBASSA-N 0.000 claims 1
- KLTBLEIMRJDBBB-UITAMQMPSA-N (5Z)-5-[(1-pyridin-2-ylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound N1=C(C=CC=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O KLTBLEIMRJDBBB-UITAMQMPSA-N 0.000 claims 1
- QRKPRYIGHVANCZ-POHAHGRESA-N (5Z)-5-[(1-pyridin-3-ylpyrazol-3-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound N1=CC(=CC=C1)N1N=C(C=C1)\C=C/1\C(NC(S\1)=S)=O QRKPRYIGHVANCZ-POHAHGRESA-N 0.000 claims 1
- XITDUDYYAZYCHU-WMZJFQQLSA-N (5Z)-5-[(1-pyridin-3-ylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound N1=CC(=CC=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O XITDUDYYAZYCHU-WMZJFQQLSA-N 0.000 claims 1
- UOBUQYLHRUUDGO-GHXNOFRVSA-N (5Z)-5-[(3-methyl-1-phenylpyrazol-4-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound CC1=NN(C=C1\C=C/1\C(NC(S\1)=O)=O)C1=CC=CC=C1 UOBUQYLHRUUDGO-GHXNOFRVSA-N 0.000 claims 1
- JBFBLQCKXXJPAX-GHXNOFRVSA-N (5Z)-5-[(5-methyl-1-phenylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound CC1=C(C=NN1C1=CC=CC=C1)\C=C/1\C(NC(S\1)=S)=O JBFBLQCKXXJPAX-GHXNOFRVSA-N 0.000 claims 1
- MTSRDAHFWUQFIR-WZUFQYTHSA-N (5Z)-5-[[1-(2-chlorophenyl)pyrazol-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound ClC1=C(C=CC=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=O)=O MTSRDAHFWUQFIR-WZUFQYTHSA-N 0.000 claims 1
- INWGVYSTIZYFCO-WZUFQYTHSA-N (5Z)-5-[[1-(2-chlorophenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC1=C(C=CC=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O INWGVYSTIZYFCO-WZUFQYTHSA-N 0.000 claims 1
- QVBXFXRJTOQKLF-QPEQYQDCSA-N (5Z)-5-[[1-(2-chlorophenyl)pyrazol-4-yl]methylidene]-3-ethyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC1=C(C=CC=C1)N1N=CC(=C1)\C=C/1\C(N(C(S\1)=S)CC)=O QVBXFXRJTOQKLF-QPEQYQDCSA-N 0.000 claims 1
- XGLRYRDGNRLUPK-SDQBBNPISA-N (5Z)-5-[[1-(2-chlorophenyl)pyrazol-4-yl]methylidene]-3-methyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC1=C(C=CC=C1)N1N=CC(=C1)\C=C/1\C(N(C(S\1)=S)C)=O XGLRYRDGNRLUPK-SDQBBNPISA-N 0.000 claims 1
- DVXBXHGOEXHJBC-WZUFQYTHSA-N (5Z)-5-[[1-(2-fluorophenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound FC1=C(C=CC=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O DVXBXHGOEXHJBC-WZUFQYTHSA-N 0.000 claims 1
- GMUDISZWGABUOF-SDQBBNPISA-N (5Z)-5-[[1-(2-methoxyphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound COC1=C(C=CC=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O GMUDISZWGABUOF-SDQBBNPISA-N 0.000 claims 1
- SQJPKUNOOYXDGU-NVNXTCNLSA-N (5Z)-5-[[1-(3,4-dimethylphenyl)pyrazol-4-yl]methylidene]-3-ethyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound CC=1C=C(C=CC=1C)N1N=CC(=C1)\C=C/1\C(N(C(S\1)=S)CC)=O SQJPKUNOOYXDGU-NVNXTCNLSA-N 0.000 claims 1
- KPJZPKNKTDAFNI-WCIBSUBMSA-N (5Z)-5-[[1-(3-chlorophenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC=1C=C(C=CC=1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O KPJZPKNKTDAFNI-WCIBSUBMSA-N 0.000 claims 1
- NCSYIOYWCOHKEX-XGICHPGQSA-N (5Z)-5-[[1-(3-chlorophenyl)pyrazol-4-yl]methylidene]-3-methyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC=1C=C(C=CC=1)N1N=CC(=C1)\C=C/1\C(N(C(S\1)=S)C)=O NCSYIOYWCOHKEX-XGICHPGQSA-N 0.000 claims 1
- RCIWQFUNMDSAFO-WCIBSUBMSA-N (5Z)-5-[[1-(3-fluorophenyl)pyrazol-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound FC=1C=C(C=CC=1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=O)=O RCIWQFUNMDSAFO-WCIBSUBMSA-N 0.000 claims 1
- GGTKKPSINFGTCM-WCIBSUBMSA-N (5Z)-5-[[1-(3-fluorophenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound FC=1C=C(C=CC=1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O GGTKKPSINFGTCM-WCIBSUBMSA-N 0.000 claims 1
- CSWCKDXMMGHTTQ-DHDCSXOGSA-N (5Z)-5-[[1-(4-butylphenyl)pyrazol-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C(CCC)C1=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=O)=O CSWCKDXMMGHTTQ-DHDCSXOGSA-N 0.000 claims 1
- GRZZBIKCCPIGLP-DHDCSXOGSA-N (5Z)-5-[[1-(4-butylphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C(CCC)C1=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O GRZZBIKCCPIGLP-DHDCSXOGSA-N 0.000 claims 1
- JXYWXHHDKWDISI-BOPFTXTBSA-N (5Z)-5-[[1-(4-butylphenyl)pyrazol-4-yl]methylidene]-3-ethyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C(CCC)C1=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(N(C(S\1)=S)CC)=O JXYWXHHDKWDISI-BOPFTXTBSA-N 0.000 claims 1
- VDAKAWNRMSEQNK-WZUFQYTHSA-N (5Z)-5-[[1-(4-chlorophenyl)pyrazol-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound ClC1=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=O)=O VDAKAWNRMSEQNK-WZUFQYTHSA-N 0.000 claims 1
- FKSGXWGJSHVGQQ-QPEQYQDCSA-N (5Z)-5-[[1-(4-chlorophenyl)pyrazol-4-yl]methylidene]-3-ethyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC1=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(N(C(S\1)=S)CC)=O FKSGXWGJSHVGQQ-QPEQYQDCSA-N 0.000 claims 1
- ALWCIRKZFNMQRO-SDQBBNPISA-N (5Z)-5-[[1-(4-chlorophenyl)pyrazol-4-yl]methylidene]-3-methyl-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound ClC1=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(N(C(S\1)=S)C)=O ALWCIRKZFNMQRO-SDQBBNPISA-N 0.000 claims 1
- NEPGOCUKNORYKY-WZUFQYTHSA-N (5Z)-5-[[1-(4-fluorophenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound FC1=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O NEPGOCUKNORYKY-WZUFQYTHSA-N 0.000 claims 1
- DCLVHSUUZOKLDZ-SDQBBNPISA-N (5Z)-5-[[1-(4-methylphenyl)pyrazol-4-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound C1(=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=O)=O)C DCLVHSUUZOKLDZ-SDQBBNPISA-N 0.000 claims 1
- MIPNDCNRMXTFEY-SDQBBNPISA-N (5Z)-5-[[1-(4-methylphenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1(=CC=C(C=C1)N1N=CC(=C1)\C=C/1\C(NC(S\1)=S)=O)C MIPNDCNRMXTFEY-SDQBBNPISA-N 0.000 claims 1
- DZBOJHSPQXHPEC-WDZFZDKYSA-N (5z)-5-[(1-phenylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound O=C1NC(=S)S\C1=C/C1=CN(C=2C=CC=CC=2)N=C1 DZBOJHSPQXHPEC-WDZFZDKYSA-N 0.000 claims 1
- ABQQQKQJNYSGAO-JYRVWZFOSA-N (5z)-5-[(3,5-dimethyl-1-phenylpyrazol-4-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound CC1=NN(C=2C=CC=CC=2)C(C)=C1\C=C1/SC(=S)NC1=O ABQQQKQJNYSGAO-JYRVWZFOSA-N 0.000 claims 1
- NRXAIYMSWFXNLC-WZUFQYTHSA-N (5z)-5-[[1-(4-chlorophenyl)pyrazol-4-yl]methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC(Cl)=CC=C1N1N=CC(\C=C/2C(NC(=S)S\2)=O)=C1 NRXAIYMSWFXNLC-WZUFQYTHSA-N 0.000 claims 1
- QQPGEFNKQAVDPB-UHFFFAOYSA-N 1-(2-methoxyphenyl)pyrazole Chemical compound COC1=CC=CC=C1N1N=CC=C1 QQPGEFNKQAVDPB-UHFFFAOYSA-N 0.000 claims 1
- WITMXBRCQWOZPX-UHFFFAOYSA-N 1-phenylpyrazole Chemical compound C1=CC=NN1C1=CC=CC=C1 WITMXBRCQWOZPX-UHFFFAOYSA-N 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Claims (12)
- R1は、水素;置換又は無置換のC1~C3直鎖又は分岐アルキル;C2~C3アルケニル;C3~C6ヘテロアリールアルキル;又は、C1~C3直鎖又は分岐ヒドロキシアルキルであることを特徴とする請求項1に記載の化合物又はその薬学的に許容可能な塩。
- R2は、水素;又は置換又は無置換のC1~C3直鎖又は分岐アルキルであることを特徴とする請求項1又は2に記載の化合物又はその薬学的に許容可能な塩。
- R3は、置換又は無置換のC1~C3直鎖又は分岐アルキル;C6~C10アリール;又はC3~C10ヘテロアリールであり、これらが置換される場合、その置換基は、ハロゲン;C1~C5直鎖又は分岐アルキル;及びC1~C5アルコキシからなる群から選択されることを特徴とする請求項1~3のいずれかに記載の化合物又はその薬学的に許容可能な塩。
- Y1は硫黄であり、Y2は酸素であることを特徴とする請求項1~4のいずれかに記載の化合物又はその薬学的に許容可能な塩。
- 前記化合物は、(5Z)-5-[(1-フェニルピラゾール-4-イル)メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-(2-フリルメチル)-5-[(1-メチルピラゾール-4-イル)メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-メチル-5-[(1-フェニルピラゾール-4-)メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-エチル-5-[(1-フェニルピラゾール-4-イル)メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-アリル-5-[(1-フェニルピラゾール-4-イル)メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-フルオロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3-フルオロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(4-フルオロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-クロロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-クロロフェニル)ピラゾール-4-イル]メチレン]-3-メチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-クロロフェニル)ピラゾール-4-イル]メチレン]-3-エチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-アリル-5-[[1-(2-クロロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3-クロロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3-クロロフェニル)ピラゾール-4-イル]メチレン]-3-メチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3-クロロフェニル)ピラゾール-4-イル]メチレン]-3-エチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-アリル-5-[[1-(3-クロロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(4-クロロフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(4-クロロフェニル)ピラゾール-4-イル]メチレン]-3-メチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(4-クロロフェニル)ピラゾール-4-イル]メチレン]-3-エチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(p-トリル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-メチル-5-[[1-(p-トリル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-エチル-5-[[1-(p-トリル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-アリル-5-[[1-(p-トリル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(4-イソプロピルフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-エチル-5-[[1-(4-イソプロピルフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(4-ブチルフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(4-ブチルフェニル)ピラゾール-4-イル]メチレン]-3-エチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3,4-ジメチルフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3,4-ジメチルフェニル)ピラゾール-4-イル]メチレン]-3-エチル-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-メトキシフェニル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-ナフチル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-エチル-5-[[1-(2-ナフチル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-ピリジル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-(2-ヒドロキシエチル)-5-[[1-(2-ピリジル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3-ピリジル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-3-(2-ヒドロキシエチル)-5-[[1-(3-ピリジル)ピラゾール-4-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[(5-メチル-1-フェニル-ピラゾール-4-イル)メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[(3,5-ジメチル-1-フェニル-ピラゾール-4-イル)メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[(1-フェニルピラゾール-4-イル)メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(2-フルオロフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2、4-ジオン、(5Z)-5-[[1-(3-フルオロフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(4-フルオロフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(2-クロロフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(3-クロロフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(4-クロロフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(p-トリル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(4-イソプロピルフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(4-ブチルフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(3,4-ジメチルフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(2-メトキシフェニル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(2-ナフチル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(3-ピリジル)ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[(3-メチル-1-フェニル-ピラゾール-4-イル)メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[(3,5-ジメチル-1-フェニル-ピラゾール-4-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(4-クロロフェニル)ピラゾール-3-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(2-ピリジル)ピラゾール-3-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-(3-ピリジル)ピラゾール-3-イル]メチレン]-2-チオキソ-チアゾリジン-4-オン、(5Z)-5-[[1-フェニルピラゾール-3-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(2-ピリジル)ピラゾール-3-イル]メチレン]チアゾリジン-2,4-ジオン、(5Z)-5-[[1-(3-ピリジル)ピラゾール-3-イル]メチレン]チアゾリジン-2,4-ジオン、及び(5Z)-5-[[1-(4-ピリジル)ピラゾール-3-イル]メチレン]チアゾリジン-2,4-ジオンからなる群から選択されることを特徴とする、請求項1に記載の化合物又はその薬学的に許容可能な塩。
- 請求項1~6のいずれかに記載の化合物又はその薬学的に許容可能な塩を有効成分として含む、mTOR(mechanistic target of rapamycin)経路関連脳疾患の予防又は治療用の薬学的組成物。
- 前記mTOR経路関連脳疾患は、てんかん、アルツハイマー病、ハンチントン病、うつ病、パーキンソン病、結節性硬化症(Tuberous sclerosis)、自閉症スペクトラム障害(Autism spectrum disorder)、カウデン症候群(Cowden syndrome)、バナヤン・ライリー・ルバルカバ症候群(Bannayan-riley-rulvalcaba syndrome)、レルミット・ダクロス病(Lhermitte-Duclos disease)、神経線維腫症(Neurofibromatosis)、第1型の神経線維腫症(Neurofibromatosis type 1)、自閉症(Autism)、非症候群性自閉症(Nonsyndromic autism)、及び統合失調症(Schizophrenia)からなる群から選択されることを特徴とする、 請求項8に記載の薬学的組成物。
- mTOR(mechanistic target of rapamycin)経路関連脳疾患の予防又は治療用製剤を製造するための、請求項1~6のいずれかに記載の化合物又はその薬学的に許容可能な塩の使用。
- 請求項1~6のいずれかに記載の化合物又はその薬学的に許容可能な塩を有効成分として含む組成物の有効量を、これを必要とする対象に投与する段階を含む、mTOR(mechanistic target of rapamycin)経路関連脳疾患の治療方法。
- 前記mTOR経路関連脳疾患は、てんかん、アルツハイマー病、ハンチントン病、うつ病、パーキンソン病、結節性硬化症(Tuberous sclerosis)、自閉症スペクトラム障害(Autism spectrum disorder)、カウデン症候群(Cowden syndrome)、バナヤン・ライリー・ルバルカバ症候群(Bannayan-riley-rulvalcaba syndrome)、レルミット・ダクロス病(Lhermitte-Duclos disease)、神経線維腫症(Neurofibromatosis)、第1型の神経線維腫症(Neurofibromatosis type 1)、自閉症(Autism)、非症候群性自閉症(Nonsyndromic autism)と統合失調症(Schizophrenia)からなる群から選択されることを特徴とする、請求項11に記載の治療方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0048774 | 2018-04-26 | ||
KR20180048774 | 2018-04-26 | ||
PCT/KR2019/005108 WO2019209083A1 (ko) | 2018-04-26 | 2019-04-26 | mTOR 저해제로서의 신규 화합물 및 이의 용도 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021527629A JP2021527629A (ja) | 2021-10-14 |
JPWO2019209083A5 true JPWO2019209083A5 (ja) | 2022-03-03 |
JP7491510B2 JP7491510B2 (ja) | 2024-05-28 |
Family
ID=68295273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020560378A Active JP7491510B2 (ja) | 2018-04-26 | 2019-04-26 | mTOR阻害剤としての新規化合物及びその用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11649231B2 (ja) |
EP (1) | EP3786163A4 (ja) |
JP (1) | JP7491510B2 (ja) |
KR (1) | KR102308134B1 (ja) |
CN (1) | CN112368279B (ja) |
WO (1) | WO2019209083A1 (ja) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3615608A (en) * | 1966-03-11 | 1971-10-26 | Eastman Kodak Co | Silver halide emulsions containing cyanine and merocyanine dyes having a 4-pyrazole nucleus |
JP2003264010A (ja) * | 2002-03-07 | 2003-09-19 | Mitsubishi Paper Mills Ltd | 光電変換素子 |
AU2003225669A1 (en) * | 2002-09-26 | 2004-04-19 | Pintex Pharmaceuticals, Inc. | Pin1-modulating compounds and methods of use thereof |
US20050065066A1 (en) * | 2002-12-20 | 2005-03-24 | Kaarsholm Niels Christian | Stabilised insulin compositions |
WO2004093803A2 (en) * | 2003-04-16 | 2004-11-04 | Pintex Pharmaceuticals, Inc. | Photochemotherapeutic compounds for use in treatment of pin1-associated states |
JP2007022998A (ja) * | 2005-07-21 | 2007-02-01 | Kyowa Hakko Kogyo Co Ltd | ラパマイシン標的蛋白質阻害剤 |
JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
UY31952A (es) * | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
CN102078318A (zh) * | 2009-11-27 | 2011-06-01 | 华东理工大学 | 5-取代-2,4-噻唑烷二酮类化合物在制备igf1r功能调节药物中的应用 |
GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US20140378436A9 (en) * | 2010-11-24 | 2014-12-25 | Exelixis, Inc. | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture |
BR102013022402B1 (pt) * | 2013-09-02 | 2020-09-15 | Universidade Federal Do Rio Grande Do Sul | Derivados benziltiazolidinônicos úteis no tratamento da esquizofrenia |
US10318613B2 (en) | 2015-08-25 | 2019-06-11 | Myscript | System and method of digital note taking |
KR102297505B1 (ko) | 2016-03-07 | 2021-09-01 | 재단법인 의약바이오컨버젼스연구단 | Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법 |
WO2017160069A1 (ko) | 2016-03-15 | 2017-09-21 | 재단법인 의약바이오컨버젼스연구단 | 신규한 벤젠설폰아미드 유도체 및 이의 용도 |
KR102304478B1 (ko) * | 2016-04-04 | 2021-09-24 | 주식회사 바오밥에이바이오 | Ras를 분해하는 이종원자고리화합물 및 이의 용도 |
EP3480596A4 (en) | 2016-07-01 | 2020-07-22 | Medicinal Bioconvergence Research Center | COMPOSITION FOR DIAGNOSING A FOLLICULAR THYROID CARCINOMA USING THE EXPRESSION LEVEL OF AN AMINOACYL-TRNA SYNTHETASE-PROTEIN AND METHOD FOR DETECTING A DIAGNOSTIC MARKER |
KR102133929B1 (ko) | 2017-06-16 | 2020-07-14 | 재단법인 의약바이오컨버젼스연구단 | 면역세포 이동에 의한 질환의 치료제 및 이의 스크리닝 방법 |
-
2019
- 2019-04-26 JP JP2020560378A patent/JP7491510B2/ja active Active
- 2019-04-26 WO PCT/KR2019/005108 patent/WO2019209083A1/ko unknown
- 2019-04-26 EP EP19792007.7A patent/EP3786163A4/en active Pending
- 2019-04-26 KR KR1020190049372A patent/KR102308134B1/ko active IP Right Grant
- 2019-04-26 CN CN201980043577.1A patent/CN112368279B/zh active Active
-
2020
- 2020-10-26 US US17/080,497 patent/US11649231B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3119755B1 (en) | Antifungal compound process | |
EP3349586B1 (en) | Antifungal compound process | |
CN101370786B (zh) | 取代的咪唑以及其作为杀虫剂的用途 | |
US7902232B2 (en) | Substituted arylpyrazoles | |
ES2338699T3 (es) | Arilpirazoles sustituidos para uso contra parasitos. | |
AU2015231226B2 (en) | Antifungal compound process | |
US7435753B2 (en) | Substituted arylpyrazoles | |
EP3119771B1 (en) | Antifungal compound process | |
JP2012501313A5 (ja) | ||
EP3148972B1 (en) | Pyrazolone derivatives as nitroxyl donors | |
CA2942231A1 (en) | Antifungal compound process | |
JP2018502906A5 (ja) | ||
JP2005506308A5 (ja) | ||
RU2000128658A (ru) | Тиенилазолилалкоксиэтанамны, их производные и их применение в качестве лекарственных средств | |
IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
CN107709301B (zh) | 吡唑衍生物或其药理学上可接受的盐 | |
AU2015231216A1 (en) | Antifungal compound process | |
JPH07502022A (ja) | トリアゾール抗真菌剤 | |
JPWO2019209083A5 (ja) | ||
CZ4296A3 (en) | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclyl)methylamine derivatives | |
CA2411760A1 (fr) | Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase | |
JP2012509249A5 (ja) |